Practical management of pediatric growth hormone deficiency with lonapegsomatropin

Lonapegsomatropin (TransCon hGH) is the first FDA approved once-weekly prodrug of somatropin for pediatric growth hormone deficiency (GHD). In the pivotal phase 3 heiGHt trial, lonapegsomatropin demonstrated noninferior and superior annualized height velocity (AHV) and a comparable safety profile to daily somatropin in treatment-na ïve children with GHD. Efficacy and safety were demonstrated in previously treated children with GHD who switched to lonapegsomatropin from their prior daily growth hormone, and long term tolerability, safety and efficacy has been demonstrated in the ongoing open-label extension trial enliGHten.
Source: Journal of Pediatric Nursing - Category: Nursing Authors: Source Type: research